Blistex Baby Kanka

Description

KANKA is a topical gel formulation containing 0.1 g of benzocaine as the active ingredient. It is designed for immediate relief of pain associated with teething and provides soothing effects for discomfort caused by dental eruption. The gel is flavored with grape (sabor uva) and is packaged in a net content of 10 g.

Uses and Indications

This drug is indicated for the topical relief of discomfort associated with teething in infants. BABY KANK-A provides immediate alleviation of pain and soothes discomfort caused by dental eruption. The formulation features a pleasant grape flavor and is designed for ease of application.

There are no teratogenic or nonteratogenic effects associated with this product.

Dosage and Administration

Healthcare professionals should instruct patients to wash their hands thoroughly before application. The tube should be opened, and the tip should be cut at the indicated mark using previously disinfected scissors.

A small amount of Baby Kank-a should be applied using the fingertip or a swab, gently rubbing it onto the injured or affected area. This application may be performed no more than four times a day, or as directed by a physician.

Contraindications

El uso de este medicamento está contraindicado en pacientes con antecedentes de alergia a este medicamento.

Warnings and Precautions

Es fundamental que los profesionales de la salud tengan en cuenta las siguientes advertencias y precauciones al considerar el uso de este medicamento.

Se recomienda que, si las molestias persisten, el paciente consulte a su médico para una evaluación adecuada y para determinar si es necesario modificar el tratamiento. La persistencia de síntomas puede indicar la necesidad de una revisión más exhaustiva de la condición del paciente.

Este medicamento debe mantenerse fuera del alcance de los niños para prevenir el riesgo de ingestión accidental, lo que podría resultar en efectos adversos graves. Es responsabilidad del profesional de la salud asegurar que los pacientes y sus cuidadores comprendan la importancia de esta medida de seguridad.

Además, es imperativo no utilizar este medicamento en pacientes con antecedentes de alergia a este fármaco. La administración en estos casos puede provocar reacciones adversas severas, por lo que se debe realizar una evaluación cuidadosa de la historia clínica del paciente antes de la prescripción.

Se sugiere que los profesionales de la salud realicen un seguimiento adecuado y consideren la implementación de pruebas de laboratorio pertinentes si se presentan síntomas inusuales o si el paciente tiene un historial médico que justifique una vigilancia adicional.

Side Effects

Patients should be advised to consult their physician if discomfort persists. It is important to keep this medication out of reach of children to prevent accidental ingestion or misuse.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Blistex Baby Kanka (benzocaine). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Infants may use BABY KANK-A to relieve discomfort associated with teething. A small amount should be applied to the affected area no more than four times a day or as directed by a physician.

Caution is advised in pediatric patients with a known history of allergy to this medication. Additionally, it is important to keep BABY KANK-A out of reach of children to prevent accidental ingestion or misuse.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

There is no specific information available regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions that should be taken. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients and weigh the potential risks and benefits. Women of childbearing potential should be counseled on the absence of established safety data in pregnancy and the importance of discussing any plans for pregnancy or breastfeeding with their healthcare provider.

Lactation

No information related to nursing mothers or lactation is provided in the drug insert for Blistex Baby Kanka (benzocaine gel). Therefore, the effects on breastfed infants and the excretion of benzocaine in breast milk are not known. Healthcare professionals should exercise caution when considering the use of this product in lactating mothers.

Renal Impairment

There is no relevant information regarding renal impairment, dosage adjustments, special monitoring, or safety considerations for patients with reduced kidney function in the provided text. Therefore, no specific recommendations or precautions can be made for this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no relevant information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely and manage any symptoms that may arise. In the absence of specific overdosage data, standard supportive care should be provided as necessary. It is recommended that healthcare providers consult local poison control centers or relevant medical guidelines for further assistance in managing potential overdosage scenarios.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

Se han recibido reportes de sospechas de reacciones adversas a través de los correos electrónicos de farmacovigilancia, específicamente a farmacovigilancia@cofepris.gob.mx y ucfarmacovigilancia@sanfer.com.mx. Estos reportes se han recopilado de manera voluntaria y a través de programas de vigilancia.

Patient Counseling

Es importante que los profesionales de la salud aconsejen a los pacientes que mantengan este medicamento fuera del alcance de los niños para prevenir el uso accidental o la ingestión inapropiada.

Los pacientes deben ser informados de que no deben utilizar este medicamento si tienen antecedentes de alergia a este mismo. Es fundamental que comprendan la importancia de informar a su médico sobre cualquier reacción alérgica previa para evitar complicaciones.

Además, se debe recomendar a los pacientes que, si las molestias persisten, consulten a su médico. Esto asegurará que reciban la atención adecuada y se evalúe la necesidad de continuar con el tratamiento o considerar alternativas.

Storage and Handling

The product is supplied in a tube that must be kept tightly sealed. It should be stored at room temperature, not exceeding 30º C. Proper storage conditions are essential to maintain the integrity of the product.

Additional Clinical Information

The product is administered topically, with a recommended application of a small amount of Baby Kank-a gently rubbed onto the affected area, not exceeding four times daily or as directed by a physician. Patients are advised to consult their doctor if discomfort persists and to keep the product out of reach of children.

No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Blistex Baby Kanka, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)